Trials / Completed
CompletedNCT00641745
Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia
Long-Term Safety, Tolerability, and Effectiveness of Lurasidone in Subjects With Schizophrenia or Schizoaffective Disorder: A Randomized, Active Comparator-Controlled Trial
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 629 (actual)
- Sponsor
- Sumitomo Pharma America, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is safe and tolerable long term among clinically stable patients. The study will also assess the long term effectiveness of lurasidone as compared to an active comparator.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lurasidone HCl | 40 - 120mg per day |
| DRUG | Risperidone | Risperidone |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2010-07-01
- Completion
- 2010-07-01
- First posted
- 2008-03-24
- Last updated
- 2015-06-22
- Results posted
- 2011-10-06
Locations
73 sites across 8 countries: United States, Argentina, Brazil, Chile, Croatia, Israel, South Africa, Thailand
Source: ClinicalTrials.gov record NCT00641745. Inclusion in this directory is not an endorsement.